The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2019 | Transcription factor alterations in AML and risk: RUNX, CEPBA & EVI1
Ruud Delwel
• 15 Mar 2019
Ruud Delwel, PhD, of the Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands, discusses transcription factor alterations in acute myeloid leukemia (AML), and how these affect disease risk and response to treatment. Dr Delwel covers RUNX1, C/EBPα, and EVI1, which is a key focus of his lab. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
